DOCSLIB.ORG

Screening of Specific Inhibitors for Human Carboxylesterases Or Arylacetamide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Screening of Specific Inhibitors for Human Carboxylesterases Or Arylacetamide Screening of Specific Inhibitors for Human Carboxylesterases or Arylacetamide Deacetylase Mai Shimizu, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi Drug Metab Dispos Supplemental Table 1. Chemicals used in this study. Alfa Aesar (Tokyo, Japan) 3-(4-Fluorobenzoyl) propiponic Acid, 3-Methylflavone-8-carboxylic acid BD Gentest (Woburn, MA) a25-Hydroxycholesterol, b4'-Hydroxydiclofenac, b5-Hydroxydiclofenac Biomol international (Plymouth Meeting, PA) Pizotifen malate Merk (Darmstadt, Germany) Mevastatin, Resveratrol Carbosynthe (Berkshire, UK) N-Acetyl-l-cysteine, Adefovir, 5,6-Dichlorobenzimidazole 1-β-d-Riboburanoside, Indiplon, Milnacipran hydrochloride, Pyridoxal 5'-phosphate Cayman Chemical (Ann Arbor, MI) N-(4-Hydroxyphenyl)-arachidonoyl amide, JW480 Dojindo Laboratories (Kumamoto, Japan) N-Cyclohexyl-3-aminopropanesulfonic acid, 3,3'-Diaminobenzidine tetrahydrochloride, Ethylene glycol-bis (β-aminoethylether)-N,N,N',N'-tetraacetic acid Enzo Life Science (Farmingdale, NY) Castanospermine, Pregnenolone-16α-carbonitrate Fujicco (Kobe, Japan) Daidzein Funakoshi (Tokyo, Japan) Blasticidin S hydrochloride, Chloroquine, Coumarin, Diethyldithiocarbamate, 7-Ethoxy-4-(trifluoromethyl) coumarin, Furafylline, G-418 sulfate, Ketoconazole, MelQ, l-α-Phosphatidyl choline dilauroyl, Potassium ferricyanide, SKF-525A, Tetrabutylammonium hydrogen sulfate, WST-1 Life Technologies (Catlsbad, CA) Cadmium Chloride LKT Laboratories (St. Paul, MN) Bestatin hydrochloride, Capecitabine, Clotrimazole, Doxifluridine, Enalaprilat, Ezetimibe, Ftorafur, Indole-3-carbinol, Montelukast, Rebamipide, Rosiglitazone, Tegafur, bTelmisartan, Temocapril hydrochloride, Terazosin hydrochloride, Tolmetin sodium, Toremifene base MP Biochemicals (Tokyo, Japan) Arachidonic acid Nacalai Tesque (Kyoto, Japan) Sodium laurylsulfate Research Organics (Cleveland, OH) N-Acetyl procainamide hydrochloride Santa Cruz Biotechnology (Santa Cruz, CA) Benzyl-2-acetamido-2-deoxy-α-d-galactopyranoside, Camostat mesylate, (+)-Clopidogrel hydrogen sulfate, Dicloxacillin sodium salt monohydrate, d-Mannose-6-phosphate disodium salt, Metyrapon, 1-Naphthyl acetate, α-Naphthoflavone, Ondansetron hydrochloride, Perphenazine, Sparteine, Sulfaphenazole, Thiouric acid sodium salt dehydrate, Tryptamine hydrochloride, WY-14643 Sigma-Aldrich Acebutolol hydrochloride, Acemetacin, p-Acetamidobenzoic acid, 9-Acetylanthracene, Acetyl-dl-carnitine hydrochloride, Amantadine hydrochloride, p-Aminobenzoic acid, 2-Aminobenzylalcohol, 6-Aminochrysene, 2-Aminofluorene, Amiodarone hydrochloride, Ammonium pyrrolidinedithiocarbamate, 5α-Androstane-3α,17β-diol, 2-Anthramine, Astaxanthin, 5-Azacytidine, Barbital, Bezafibrate, Benzbromarone, 6-Benzyl-2-thiouracil, 5-Bromouracil, Bupropion, Busulfan, l-Buthionine-[S,R]-sulfoximine, Caffeine, Cefamandole, Cefoperazone, 2-Chloro-3',4'-dimethoxybenzil, 5-Chlorouracil, Chlorpropamide, Chlorzoxazone, Chrysin, Clofibric acid, Cloxacillin sodium salt monohydrate, (-)-Cotinine, Cyclobenzaprine hydrochloride, Dapson, Deferoxamine mesylate salt, Dehydroisoandrosterone-3-sulfate, Deoxycorticosterone, Diazepam, Diclofenac sodium salt, (-)-3-(3,4-Dihydroxyphenyl)-2-methyl-l-alanine sesquihydrate, 2,6-Dihydroxypyridine hydrochloride, Dimethyl pimelimidate dihydrochloride, Diosmin, Doxepin hydrochloride, 17-Epiestriol, (-)-Epinephrine (+)-bitartratee, β-Estradiol, Estriol, Estrone, Estrone 3-sulfate potassium salt, dl-Ethionine, 7-Ethoxycoumarin, Ethoxyresorufin, 5-Ethyl-5-p-tolybarbituric acid, Fenbendazole, Fenofibrate, Ficoll 400, Flunitrazepam, 5-Fluoro-2'-deoxyuridine, 5-Fluorouridine, Fluoxetine, Flurbiprofen, Gadolinium (III) chloride hexahydrate, Hecogenin acetate, Hexobarbital, Hydralazine hydrochloride, 3-Hydroxybenzylhydrazine dihydrochloride, 7-Hydroxycoumarin, 12-Hydroxydodecanoic acid, 11β-Hydroxytestosterone, 3-Hydroxybenzylhydrazine dihydrochloride 2-Hydroxy-1,4-naphthoquinone, 5-(3-Hydroxyphenyl)-5-phenylhydantoin, 5-(4-Hydroxyphenyl)-5-phenylhydantoin, 17α-Hydroxyprogesterone, 7-(β-Hydroxypropyl) theophylline, dl-Isocitric acid, Isoniazid, Kaempferol, Labetalol hydrochloride, Lauric acid sodium salt, Z-Leu-Leu-Leu-al, Leupeptin, Levofloxacin, Loxapine succinate salt, Maprotiline hydrochloride, Methapyrilene hydrochloride, Methimazole, (S)-(+)-6-Methoxy-α-methyl-2-naphthaleneacetic acid, 3-Methylindole, 4-Methylumbelliferone, 5-(4-Methylphenyl)-5-phenyl-hydantoin, 1-Methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine hydrochloride, Nalidixic acid, Naloxone hydrochloride, β-Naphthoflavone, 1,2-Naphthoquinone, Nialamide, (-)-Nicotine, Nicotinic acid N-oxide, Nimesulide, Nimodipine, Nordihydroguaiaretic acid, l-(-)-Norepinephrine, Norfloxacin, Nortriptyline hydrochloride, Omeprazole, Oxibendazole, Oxybutiynin chloride, Paclitaxel, Pepstatin A, 1,7-Phenanthroline, Phenazine ethosulfate, p-Phenetidine, (R)-1-Phenyl-1,2-ethanediol, (S)-1-Phenyl-1,2-ethanediol, Pilocarpine hydrochloride, Polymyxin B sulfate salt, Praziquantel, Prednisolone, 5α-Pregnan-3,20-dione, 5-Pregnen-3β-ol-20-one-16α-carbonitrile, Prilocaine hydrochloride, Procainamide hydrochloride, Procaine hydrochloride, Prochlorperazine dimaleate salt, Progesterone, Proglumide, Promazine hydrochloride, (R)-(+) Propranolol hydrochloride, 6-Propyl-2-thiouracil, Protriptyline hydrochloride, Pyrazole, Quercetin, d-Saccharic acid 1,4-lactone, Sodium orthovanadate, Sulfamethazine, Tetrabutylammonium hydroxide, Thiobenzamide, l-Thyroxine, (±)-α-Tocopherol nicotinate, Triacetyloleandomycin, Trichostatin A, Trimipramine maleate, l-Tryptophan, Uracil, Uridine, Uridine 5'-diphosphate sodium salt, R,S-Warfarin, Zolpidem, Zomepirac sodium salt Steraloids (Newport, RI) 5β-Pregnan-3,20-dione Tokyo Chemical Industry (Tokyo, Japan) 1-Aminobenzotriazole, 2-Amino-m-cresol, 4-Amino-3,5-xylenol, Benzo[a]anthracene, Captopril, Dehydroepiandrosterone, Delapril hydrochloride, 2,2'-Dihydroxy-4-methoxybenzophenone, Dimethyl pimelimidate dihydrochrolide, 4-Hydroxybenzoic acid n-hexyl ester, Methotrexate, Methylviologen, Mifepristone, 1-(1-Naphthyl)-2-thiourea, Oxymetholine, Spironolactone, 1,2,3,6-Tetrahydro-4-phenylpyridine hydrochloride Toronto Research Chemicals N-Acetyl dapsone, Albendazole sulfoxide, Azasetron, Bufuralol hydrochloride, Butenafin hydrochloride, Candesartan, Cefmetazole, 5-Chloro-2,4-dihydroxypyridine, Digoxin, Docetaxel, Eprosartan, Fenofibric acid, GW4064, 6-Hydroxychlorzoxazone, 3-Hydroxy desloratadine, (+/-)-4'-Hydroxy mephenytoin, Imidapril hydrochloride, Irbesartan, Irinotecan, Isocarboxazid, Losartan carboxaldehyde, Losartan carboxylic acid, Mephenytoin, Nateglinide, Olmesartan, Oxonic acid potassium salt, Pitavastatin lactone, Prasugrel hydrochloride, Quetiapine hemifumarate, Raloxifene hydrochloride, Sertraline hydrochloride, Simvastatin, SN-38, Tolcapone, 3,3',5-Triiodo-l-thyronine, Valsartan, Vanillylamine hydrochloride Ultrafine Chemicals and Minerals (Tamilnadu, India) Debrisoquine sulphate, Dextromethorphan hydrobromide, Oxydized nifedipine, Terfenadine Wako Pure Chemical Industries Acarbose, Aceclofenac, Acetanilide, Acetoaminophen, Acetohexamide, 7-Acetoxy-4-methylcoumarin, Acetylsalicylic acid, Albiflorin, Allopurinol, (p-Amidinophenyl) methanesulfonyl fluoride hydrochloride, dl-2-Aminobutyric acid, Aminoguanidine hydrochloride, 6-Aminohexanoic acid, 5-Aminolevulinic acid hydrochloride, 1-Amino-2-methylindoline, 2-Amino-5-nitrobenzophenone, 5-Amino-2-nitrobenztrifluoride, 3-Aminophenol, 3-Amino-1H-1,2,4-triazole, 4-Amino-1,2,4-triazole, 4-Amino-2-(trifluoromethyl)benzonitrile, Amitriptyline hydrochloride, Amoxapine, Ampicillin sodium, (+)-4-Androstene-3,17-dione, l(+)-Arabinose, 5-Aza-2'-deoxycitidine, 3'-Azido-3'-deoxythymidine, Baicalein, Baicalin, Barium hydroxide octahydrate, p-Benzoyl phenol, Benzhydrol, Benzophenone, Benzylhydrazine dihydrochloride, Bicalutamide, Bilirubin, Borneol, Buformine hydrochloride, t-Butylhydroquinone, S-Butyrylthiocholine iodide, Calcitriol, Camptothecin, Capsaicin, Carbamazepine, Carbomethoxymethylene, Carvedilol, Cefazolin sodium salt, Chenodeoxycholic acid, 3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate, Chloramphenicol, p-Chlorobenzoic acid, 4-Chloro-1-naphthol, Chlorpromazine hydrochloride, Ciclosporine, Ciprofloxacin hydrochloride monohydrate, Clarithromycin, Clomipramine hydrochloride, Clopidogrel carboxylic acid, Clozapine, Colchicine, Corticosterone, Coumarin-3-carboxylic acid, o-Cresol, p-Cresol, Cyclizine hydrochrolide, Cycloheximide, 2-Cyclohexyl-2-phenylglycolic Acid, Cyclophosphamide monohydrate, l-Cysteine, Cytidine, Cytosine-1-β-d(+)-arabinofuranoside, Dantrolene sodium, 1-Decanesulfonic acid, Desipramine hydrochloride, Dexamethasone, cis-Diammine dichloroplatinum (II), Dibucaine hydrochloride, 2,6-Di-tert-butyl-4-methylphenol, N6,2'-O-Dibutyryladenosine 3',5'-(cyclic)monophosphate sodium salt, 2,6-Dichloro-4-nitrophenol, 3,4-Dichloroaniline, 3,4-Dichloronitrobenzene, 2,6-Dichlorophenol, Digitonin, 1,2-Dihydroxy-4-nitrobenzene, dl-β-(3,4-Dihydroxyphenyl) alanine, Diltiazem hydrochloride, (±)-Dithiothreitol, p-Dimethylaminobenzaldehyde, 1,3-Dimethyluric acid, Diphenhydramine hydrochloride, Disodium molybdate (VI) dehydrate, Disulfiram, Dopamine hydrochloride, Enalapril maleate, Erythromycin, Ethacrynic acid, Ethylcarbamate, 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, N-Ethylmaleimide, Ethynylestradiol, Etizolam, Etodolac, Etoposide, Famotidine, Felbamate, Flavoxate hydrochloride, Fluconazole, Fluoranthene, p-Fluorophenyl acetic acid, 5-Fluorouracil, Flutamide, Fluvastatin sodium, o-Formylbenzoic acid, Fulvestrant, 2-Furancarboxylic,
Load more

Recommended publications
  • Multi-Residue Automated Turbulent Flow Online LC-MS/MS Method for the Determination of Antibiotics in Milk
    Multi-residue Automated Turbulent Flow 63551 Method: Online LC-MS/MS Method for the Determination of Antibiotics in Milk Katerina Bousova, Klaus Mittendorf, Thermo Fisher Scientific Food Safety Response Center, Dreieich, Germany Key Words Transcend TLX, TSQ Quantum Access MAX, Antibiotics, Food Safety, Milk, TurboFlow Technology 1. Schematic of Method Sample Shaking 1. Weigh 500 mg of shaken milk into 2 mL centrifuge tube Sample 500 mg + IS 2. Add 450 µL acetonitrile and 50 µL working IS solution 3. Vortex sample for 5 minutes Extraction 4. Centrifuge sample with 12,000 rpm for 5 minutes For fast screening of antibiotics, microbiological or bioassay techniques are widely used. These techniques 5. Filter sample through 0.45 µm nylon microfilter are not able to distinguish between the different types of antibiotics and provide only a semi-quantitative result Centrifugation and Filtration for the total amount of drug residues. The big drawback is the incidence of false-negative or false-positive results 6. Inject into TLX-LC-MS/MS because of low sensitivity and specificity. However, these screening assays are still very popular and widely used Turbulent Flow LC-MS/MS because of their cost-effectiveness and speed of analysis. For quantitative analysis it is necessary to use instrumental techniques such as LC-MS/MS. This 2. Introduction technique can also be used for screening, and provides Antibiotics are a group of chemicals that are widely used much higher sensitivity and greater specificity. The in animal husbandry primarily for protection of animals use of LC-MS/MS for screening was described in a from disease but also as growth promoters.
    [Show full text]
  • A Phase II Study of Paclitaxel and Capecitabine As a First-Line Combination Chemotherapy for Advanced Gastric Cancer
    British Journal of Cancer (2008) 98, 316 – 322 & 2008 Cancer Research UK All rights reserved 0007 – 0920/08 $30.00 www.bjcancer.com A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer Clinical Studies HJ Kang1, HM Chang1, TW Kim1, M-H Ryu1, H-J Sohn1, JH Yook2,STOh2, BS Kim2, J-S Lee1 and Y-K Kang*,1 1 2 Division of Oncology, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea Paclitaxel and capecitabine, which have distinct mechanisms of action and toxicity profiles, have each shown high activity as single agents in gastric cancer. Synergistic interaction between these two drugs was suggested by taxane-induced upregulation of thymidine phosphorylase. We, therefore, evaluated the antitumour activity and toxicities of paclitaxel and capecitabine as first-line therapy in patients with advanced gastric cancer (AGC). Patients with histologically confirmed unresectable or metastatic AGC were treated À2 À2 with capecitabine 825 mg m p.o. twice daily on days 1–14 and paclitaxel 175 mg m i.v. on day 1 every 3 weeks until disease progression or unacceptable toxicities. Between June 2002 and May 2004, 45 patients, of median age 57 years (range ¼ 38–73 years), were treated with the combination of capecitabine and paclitaxel. After a median 6 cycles (range ¼ 1–9 cycles) of chemotherapy, 43 were evaluable for toxicity and response. A total of 2 patients showed complete response and 20 showed partial response making the overall response rate 48.9% (95% CI ¼ 30.3–63.5%).
    [Show full text]
  • The Detection and Determination of Esters
    Louisiana State University LSU Digital Commons LSU Historical Dissertations and Theses Graduate School 1958 The etD ection and Determination of Esters. Mohd. Mohsin Qureshi Louisiana State University and Agricultural & Mechanical College Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_disstheses Recommended Citation Qureshi, Mohd. Mohsin, "The eD tection and Determination of Esters." (1958). LSU Historical Dissertations and Theses. 501. https://digitalcommons.lsu.edu/gradschool_disstheses/501 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Historical Dissertations and Theses by an authorized administrator of LSU Digital Commons. For more information, please contact [email protected]. Copright by Mohcl Mohsin Qureshi 1959 THE DETECTION AND DETERMINATION OF ESTERS A Dissertation Submitted to the Graduate Faculty of the Louisiana State University and Agricultural and Mechanical College in partial fulfillment of the requirements for the degree of Doctor of Philosophy in The Department of Chemistry by Mohd. Mohsin Qureshi M.Sc., Aligarh University, 1944 August, 1958 ACKNOWLEDGMENT The author wishes to express his sincere apprecia­ tion and gratitude to Dr. Philip W. West under whose guidance this research was carried out. He is grateful to Dr. James G. Traynham for sup­ plying him with a number of esters and for his many helpful suggestions. The financial support given to him by the Continental Oil Company is gratefully acknowledged. He offers his sincere thanks to Miss Magdalena Usategul for her valuable suggestions and her ungrudging help during the course of this investigation. Dr. Anil K.
    [Show full text]
  • Dopamine: a Role in the Pathogenesis and Treatment of Hypertension
    Journal of Human Hypertension (2000) 14, Suppl 1, S47–S50 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh Dopamine: a role in the pathogenesis and treatment of hypertension MB Murphy Department of Pharmacology and Therapeutics, National University of Ireland, Cork, Ireland The catecholamine dopamine (DA), activates two dis- (largely nausea and orthostasis) have precluded wide tinct classes of DA-specific receptors in the cardio- use of D2 agonists. In contrast, the D1 selective agonist vascular system and kidney—each capable of influenc- fenoldopam has been licensed for the parenteral treat- ing systemic blood pressure. D1 receptors on vascular ment of severe hypertension. Apart from inducing sys- smooth muscle cells mediate vasodilation, while on temic vasodilation it induces a diuresis and natriuresis, renal tubular cells they modulate sodium excretion. D2 enhanced renal blood flow, and a small increment in receptors on pre-synaptic nerve terminals influence nor- glomerular filtration rate. Evidence is emerging that adrenaline release and, consequently, heart rate and abnormalities in DA production, or in signal transduc- vascular resistance. Activation of both, by low dose DA tion of the D1 receptor in renal proximal tubules, may lowers blood pressure. While DA also binds to alpha- result in salt retention and high blood pressure in some and beta-adrenoceptors, selective agonists at both DA humans and in several animal models of hypertension. receptor classes have been studied in the treatment of
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Drug Class Review Newer Drugs for Insomnia
    Drug Class Review Newer Drugs for Insomnia Final Update 2 Report October 2008 The Agency for Healthcare Research and Quality has not yet seen or approved this report. The purpose of Drug Effectiveness Review Project reports is to make available information regarding the comparative clinical effectiveness and harms of different drugs. Reports are not usage guidelines, nor should they be read as an endorsement of or recommendation for any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Update 1: July 2006 Original: December 2005 Susan Carson, MPH Marian S. McDonagh, PharmD Sujata Thakurta, MPA:HA Po-Yin Yen, MS Drug Effectiveness Review Project Marian McDonagh, PharmD, Principal Investigator Oregon Evidence-based Practice Center Mark Helfand, MD, MPH, Director Copyright © 2008 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 2 Drug Effectiveness Review Project The medical literature relating to the topic is scanned periodically (see http://www.ohsu.edu/xd/research/centers-institutes/evidence-based-policy- center/derp/documents/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report based on the information contained in the scan. Some portions of the report may not be up to date. Prior versions of this report can be accessed at the DERP website. Insomnia Page 2 of 87 Final Report Update 2 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION ............................................................................................................. 6 Scope and Key Questions ......................................................................................................................
    [Show full text]
  • Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development
    processes Review Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development Outi M. H. Salo-Ahen 1,2,* , Ida Alanko 1,2, Rajendra Bhadane 1,2 , Alexandre M. J. J. Bonvin 3,* , Rodrigo Vargas Honorato 3, Shakhawath Hossain 4 , André H. Juffer 5 , Aleksei Kabedev 4, Maija Lahtela-Kakkonen 6, Anders Støttrup Larsen 7, Eveline Lescrinier 8 , Parthiban Marimuthu 1,2 , Muhammad Usman Mirza 8 , Ghulam Mustafa 9, Ariane Nunes-Alves 10,11,* , Tatu Pantsar 6,12, Atefeh Saadabadi 1,2 , Kalaimathy Singaravelu 13 and Michiel Vanmeert 8 1 Pharmaceutical Sciences Laboratory (Pharmacy), Åbo Akademi University, Tykistökatu 6 A, Biocity, FI-20520 Turku, Finland; ida.alanko@abo.fi (I.A.); rajendra.bhadane@abo.fi (R.B.); parthiban.marimuthu@abo.fi (P.M.); atefeh.saadabadi@abo.fi (A.S.) 2 Structural Bioinformatics Laboratory (Biochemistry), Åbo Akademi University, Tykistökatu 6 A, Biocity, FI-20520 Turku, Finland 3 Faculty of Science-Chemistry, Bijvoet Center for Biomolecular Research, Utrecht University, 3584 CH Utrecht, The Netherlands; [email protected] 4 Swedish Drug Delivery Forum (SDDF), Department of Pharmacy, Uppsala Biomedical Center, Uppsala University, 751 23 Uppsala, Sweden; [email protected] (S.H.); [email protected] (A.K.) 5 Biocenter Oulu & Faculty of Biochemistry and Molecular Medicine, University of Oulu, Aapistie 7 A, FI-90014 Oulu, Finland; andre.juffer@oulu.fi 6 School of Pharmacy, University of Eastern Finland, FI-70210 Kuopio, Finland; maija.lahtela-kakkonen@uef.fi (M.L.-K.); tatu.pantsar@uef.fi
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Hypertensive Crises 8.25
    Hypertensive Crises 8.25 Hypertension crises secondary to monoamine oxidase inhibitor–tyramine interactions Monoamine oxidase inhibitor therapy Impaired degradation of intracellular amines Ingestion of (epinephrine, norepinephrine, dopamine) tyramine-containing food Accumulation of catecholamines in Hepatic monamine nerve terminal storage granules oxidase inhibition with decreased Increased circulating oxidative metabolism tyramine level of tyramine Massive release of catecholamines Tachyarrhythmias Vasoconstriction (increased systemic vascular resistance) Severe paroxysm of hypertension Hypertensive encephalopathy Acute hypertensive heart failure with pulmonary edema Intracerebral hemorrhage (Fig. 8-21) (Figs. 8-24 and 8-25) FIGURE 8-32 Hypertensive crises secondary to monoamine oxidase inhibitor–tyramine interactions. Severe paroxysmal hypertension complicated by intracerebral or subarachnoid hemorrhage, hypertensive encephalopathy, or acute hypertensive heart failure can occur in patients treated with monoamine oxidase (MOA) inhibitors after ingestion of certain drugs or tyramine- containing foods [48,49]. Because MAO is required for degradation of intracellular amines, including epinephrine, norepinephrine, and dopamine, MAO inhibitors lead to accumulation of catecholamines within storage granules in nerve terminals. The amino acid tyramine is a potent inducer of neurotransmitter release from nerve terminals. As a result of inhibition of hepatic MAO, ingested tyramine escapes oxidative degradation in the liver. In addition, the high circulating levels of tyramine provoke massive catecholamine release from nerve terminals, resulting in vasoconstriction and a paroxysm of severe hypertension. A hyper- adrenergic syndrome resembling pheochromocytoma then ensues. Symptoms include severe pounding headache, flushing or pallor, profuse diaphoresis, nausea, vomiting, and extreme prostration. The mean increase in blood pressure is 55 mm Hg systolic and 30 mm Hg diastolic [49]. The duration of the attacks varies from 10 minutes to 6 hours.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Cholecystokinin Octapeptide Antagonized Opioid Analgesia Mediated by /T- and R- but Not Cs-Receptors in the Spinal Cord of the Rat
    Brain Research, 523 (1990) 5-10 5 Elsevier BRES 15696 Cholecystokinin octapeptide antagonized opioid analgesia mediated by /t- and r- but not cS-receptors in the spinal cord of the rat Xiao-Jing Wang, Xiao-Hong Wang and Ji-Sheng Han Department of Physiology, Beijing Medical University, Beijing (People's Republic of China) (Accepted 23 January 1990) Key words: Cholecystokinin octapeptide; (N-MePhea,o-Pro4) Morphiceptin; (N-MeTyrl,N-MeArg7,D-Leu 8) Dynorphin(1-8) ethylamide; (D-Pen 2'5) Enkephalin; Proglumide; Intrathecal injection; Opioid analgesia; Antiopioid effect Intrathecal (ith) injection of cholecystokinin octapeptide (CCK-8) to the rat with single dose of 4 or 40 ng, or successive doses from 0.1 to 1/ag at 10 rain intervals produced neither analgesia nor hyperalgesia. However, the analgesia produced by ith injection of PL017, a specific /~-reeeptor agonist or 66A-078, a specific r-receptor agonist could be markedly antagonized by CCK-8 at a dose as small as 4 ng. In contrast, analgesia produced by ith injection of 6-agonist DPDPE could not be blocked by CCK-8 even at a dose as high as 40 ng. Since the effect of CCK-8 could be totally reversed by the CCK receptor antagonist proglumide, this effect is most probably mediated by CCK receptors. INTRODUCTION MATERIALS AND METHODS Cholecystokinin octapeptide (CCK-8) has been known Surgical procedures and intrathecal injection of drugs Male Wistar rats weighing 200-250 g were anesthetized with as a neuropeptide of abundant and wide distribution in chlorohydrate (0.4 g/kg, i.p.). PE-10 polyethiene catheter of 7.5 cm CNS 1 with some important physiological functions in- long was implanted through the atlanto-occipital membrane down to cluding the anti-opioid effect4'9.
    [Show full text]
  • Extraction and Evaporation: Experiment 1 Separating the Components of a Mixture1 Week 1
    Organic Chemistry I Laboratory Extraction and Evaporation: Experiment 1 Separating the Components of a Mixture1 Week 1 Background Reading Zubrick, J. W. The Organic Chem Lab Survival Manual, 4th edition, Wiley & Sons, Inc., New York, 1997. Keeping a Notebook: Pg 12-24. Interpreting Handbooks: Pg 26-31, 34-44. Extraction and Washing: Pg 148-168. Background Senario One of the many places organic chemists are employed is in private laboratories associated with consulting firms. The purpose of these labs is generally to provide chemical analysis or synthesis of material for customers. The first few labs in CHM 220 will teach you the basic techniques needed to analyze and purify mixtures to determine the individual components. This first lab will involve determining the composition of a possible pharmaceutical preparation. Watchdog agencies exist which monitor the pharmaceuticals sold over the counter in the United States. These agencies will use private laboratory firms to analyze products suspected of violating enforced standards. For example, a new brand of analgesic may appear on drugstore shelves at a low price. The label indicates that the tablets were manufactured in the United States by a legitimate pharmaceutical company. However, the labels may reveal discrepancies and the appearance/quality of the tablets could lead an investigator to suspect that they might be counterfeit. Such knockoffs of a domestic product can be manufactured cheaply elsewhere and smuggled into the US, where they are sold for high profits. This laboratory exercise places you in the position of analyzing a suspected counterfeit analgesic preparation. The label on the suspected bottle lists the ingredients per tablet as aspirin (200 mg), acetaminophen (250 mg), and sucrose (50 mg).
    [Show full text]